Cognitive impairment 2 years after mild to severe SARS-CoV-2 infection in a population-based study with matched-comparison groups.

Publication date: Jul 08, 2025

COVID-19 may have long lasting cognitive consequences. Studies with a follow-up longer than 1 year after infection are lacking. This study presents the prevalence of cognitive impairment 2 years after SARS-CoV-2 infection in survivors of the first year of the pandemic and comparison groups matched 1:1 for sex, age, and level of care. Users of the Local Health Unit of Matosinhos (comprising almost all citizens of the municipality) were retrospectively selected according to hospitalization and SARS-CoV-2 infection between March 2020 and February 2021: group #1, hospitalized for COVID-19 (n = 101); group #2, hospitalized, uninfected (n = 87); group #3, non-hospitalized, infected (n = 252); group #4, non-hospitalized, uninfected (n = 258). Between July 2022 and October 2023, all participants completed the Montreal Cognitive Assessment. Those with a score below 1. 5 SD of age- and education-specific norms (n = 279) were invited for a comprehensive neuropsychological assessment to identify cognitive impairment. The prevalence of cognitive impairment was higher in group #1 than #2 (19. 1% vs. 6. 8%; adjusted OR 5. 41, 95% CI 1. 54, 19. 03) and in group #3 than #4 (10. 7% vs. 3. 2%; adjusted OR 3. 27, 95% CI 1. 23, 8. 67). These results suggest that specific care to timely diagnose and treat cognitive impairment is needed for COVID-19 survivors of the first year of the pandemic.

Open Access PDF

Concepts Keywords
February Adult
Hospitalization Aged
July Aged, 80 and over
Pandemic Cognitive Dysfunction
Cognitive impairment
COVID-19
COVID-19
Female
Hospitalization
Humans
Male
Middle Aged
Neuropsychological assessment
Neuropsychological Tests
Prevalence
Retrospective Studies
SARS-CoV-2
SARS-CoV-2 infection

Semantics

Type Source Name
disease MESH Cognitive impairment
disease MESH SARS-CoV-2 infection
pathway REACTOME SARS-CoV-2 Infection
disease MESH infection
disease MESH Long Covid
disease MESH emergency
disease MESH neurodegenerative diseases
pathway REACTOME Neurodegenerative Diseases
disease MESH sequelae
drug DRUGBANK Coenzyme M
disease IDO process
disease MESH marital status
disease MESH lifestyles
drug DRUGBANK Ethanol
disease MESH Anxiety
disease MESH Depression
disease MESH sleep quality
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH dementia
disease MESH Hypertension
disease MESH Hypercholesterolemia
disease MESH Obesity
disease MESH Glaucoma
disease MESH Heart failure
disease MESH Arrhythmia
disease MESH Stroke
disease MESH Transient ischemic attack
disease MESH Epilepsy
disease MESH Asthma
pathway KEGG Asthma
disease MESH Rhinitis
disease MESH Pulmonary emphysema
disease MESH Chronic bronchitis
disease MESH Obstructive sleep apnea
disease MESH Hypothyroidism
disease MESH Hyperthyroidism
disease MESH Osteoporosis
disease MESH Osteoarthritis
disease MESH Rheumatoid arthritis
pathway KEGG Rheumatoid arthritis
disease MESH Hernia
disease MESH Urinary incontinence
disease MESH Allergies
drug DRUGBANK Timonacic

Original Article

(Visited 2 times, 1 visits today)